TG Therapeutics saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of TG Therapeutics’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
TG Therapeutics has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 100% grants. The United States(US) patent Office are among the top ten patent offices where TG Therapeutics is filings its patents. Among the top granted patent authorities, TG Therapeutics has 100% of its grants in United States(US).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for TG Therapeutics
Multiple sclerosis related patents lead TG Therapeutics portfolio
TG Therapeutics has highest number of patents in multiple sclerosis.
For comprehensive analysis of TG Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
